ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Carmell Corporation

Carmell Corporation (CTCX)

2.57
0.0599
(2.39%)
Closed May 27 4:00PM
2.45
-0.12
(-4.67%)
After Hours: 6:06PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.45
Bid
2.00
Ask
3.32
Volume
85,562
2.46 Day's Range 2.65
1.70 52 Week Range 13.051
Market Cap
Previous Close
2.5101
Open
2.64
Last Trade
1
@
3
Last Trade Time
Financial Volume
$ 218,383
VWAP
2.5523
Average Volume (3m)
8,870
Shares Outstanding
23,081,642
Dividend Yield
-
PE Ratio
-3.79
Earnings Per Share (EPS)
-0.7
Revenue
-
Net Profit
-16.12M

About Carmell Corporation

Carmell Corporation (CTCX) is a bio-aesthetics company that utilizes the Carmell SecretomeTM to support skin and hair health. The Carmell SecretomeTM consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-... Carmell Corporation (CTCX) is a bio-aesthetics company that utilizes the Carmell SecretomeTM to support skin and hair health. The Carmell SecretomeTM consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-approved tissue banks. Over the past seven years, Carmell has extensively tested the technology underpinning the Carmell SecretomeTM. In addition, Carmell has developed a novel microemulsion formulation that enables the delivery of lipophilic and hydrophilic ingredients without relying on the Foul FourteenTM, which are 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Additionally, Carmell's microemulsion formulations do not utilize mineral or vegetable oils across its entire product line and are designed to be non-comedogenic. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
1970
Carmell Corporation is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker CTCX. The last closing price for Carmell was $2.51. Over the last year, Carmell shares have traded in a share price range of $ 1.70 to $ 13.051.

Carmell currently has 23,081,642 shares outstanding. The market capitalization of Carmell is $61.17 million. Carmell has a price to earnings ratio (PE ratio) of -3.79.

CTCX Latest News

Carmell Announces Successful Closing of $3.0 Million Private Placement

PITTSBURGH, April 11, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”...

Carmell Announces $3.0 Million Private Placement

PITTSBURGH, April 04, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”...

Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction

PITTSBURGH, March 27, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”...

Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary

PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”...

Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field

PITTSBURGH, March 18, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced it will...

Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024

PITTSBURGH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell” or the “Company”), today announced that they...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.3215.02347417842.132.932.05294032.41350323CS
40.2511.36363636362.22.931.82125312.28904004CS
12-0.85-25.75757575763.33.351.740188702.4237108CS
26-0.35-12.52.84.31281.740187522.92388594CS
52-5.25-68.18181818187.713.0511.71291854.22697686CS
156-5.25-68.18181818187.713.0511.71291854.22697686CS
260-5.25-68.18181818187.713.0511.71291854.22697686CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

CTCX Discussion

View Posts
stock1ace1 stock1ace1 10 months ago
Carmell Announces Successful Closing of Merger with Axolotl Biologix and Launch of a New Brand Identity

https://www.businesswire.com/news/home/20230809916251/en/Carmell-Announces-Successful-Closing-of-Merger-with-Axolotl-Biologix-and-Launch-of-a-New-Brand-Identity
👍️0
stock1ace1 stock1ace1 10 months ago
CTCX $2.90 #merger complete rsi 22 oversold macd crossover bullish

https://stockcharts.com/h-sc/ui?s=Ctcx
👍️0
AJ Freely AJ Freely 10 months ago
$CTCX - Announces Merger with Axolotl Biologix, a Profitable Regenerative Medicine Company
Up 57% Pre-Market/ Current Price $4.74
👍️0
Monksdream Monksdream 10 months ago
Carmell Therapeutics Corp NASDAQ: CTCX*

GoSymbol lookup
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Company profile
Carmell Therapeutics Corporation is a regenerative medicine platform company. The Company is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. The Company’s lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing the Company’s core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The Company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.
Carmell Therapeutics Corp NASDAQ: CTCX*

GoSymbol lookup
*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements
Health Care : Biotechnology | Company profile
Carmell Therapeutics Corporation is a regenerative medicine platform company. The Company is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. The Company’s lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing the Company’s core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The Company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.
👍️0

Your Recent History

Delayed Upgrade Clock